APVO (Aptevo Therapeutics) Interest Expense : $0.00 Mil (TTM As of Dec. 2024)

View and export this data going back to 2016. Start your Free Trial

What is Aptevo Therapeutics Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Aptevo Therapeutics's interest expense for the three months ended in Dec. 2024 was $ 0.00 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2024 was $0.00 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Aptevo Therapeutics's Operating Income for the three months ended in Dec. 2024 was $ -6.38 Mil. Aptevo Therapeutics's Interest Expense for the three months ended in Dec. 2024 was $ 0.00 Mil. GuruFocus does not calculate Aptevo Therapeutics's interest coverage with the available data. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Aptevo Therapeutics Interest Expense Historical Data

The historical data trend for Aptevo Therapeutics's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aptevo Therapeutics Interest Expense Chart

Aptevo Therapeutics Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Interest Expense

Get a 7-Day Free Trial

Aptevo Therapeutics Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Interest Expense	Get a 7-Day Free Trial															-	-	-	-	-

Aptevo Therapeutics Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Aptevo Therapeutics (NAS:APVO) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Aptevo Therapeutics's Interest Expense for the three months ended in Dec. 2024 was $0.00 Mil. Its Operating Income for the three months ended in Dec. 2024 was $-6.38 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Dec. 2024 was $4.63 Mil.

Aptevo Therapeutics's Interest Coverage for the quarter that ended in Dec. 2024 is calculated as

GuruFocus does not calculate Aptevo Therapeutics's interest coverage with the available data.

The higher the ratio, the stronger the company's financial strength is.

Aptevo Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aptevo Therapeutics Inc (NAS:APVO) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

2401 4th Avenue, Suite 1050, Seattle, WA, USA, 98121

Website

https://www.aptevotherapeutics.com

Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.

Executives

Daphne Taylor	officer: SVP, CFO	3303 MONTE VILLA PARKWAY, BOTHELL WA 98021
Kevin C Tang	10 percent owner	4747 EXECUTIVE DRIVE, SUITE 210, SAN DIEGO CA 92121
Soyoung Kwon	officer: See Remarks	APTEVO THERAPEUTICS INC., 2401 4TH AVENUE, SUITE 1050, SEATTLE WA 98121
Tang Capital Management Llc	10 percent owner	4747 EXECUTIVE DRIVE, SUITE 210, SAN DIEGO CA 92121
Tang Capital Partners Lp	10 percent owner	4747 EXECUTIVE DRIVE, SUITE 210, SAN DIEGO CA 92121
Randy Joe Maddux	officer: Senior VP, Operations	2401 4TH AVENUE, SUITE #1050, SEATTLE WA 98121
Fuad El-hibri	director	2273 RESEARCH BLVD, SUITE 400, ROCKVILLE MD 20850
Daniel Abdun-nabi	director	400 PROFESSIONAL DRIVE, SUITE 400, GAITHERSBURG MD 20879
Marvin L White	director, officer: President and CEO	2273 RESEARCH BLVD, SUITE 400, ROCKVILLE MD 20850
Barbara Lopez Kunz	director	2401 4TH AVENUE, SUITE 1050, SEATTLE WA 98121
Zsolt Harsanyi	director	2273 RESEARCH BLVD., SUITE 400, ROCKVILLE MD 20850
Grady Iii Grant	director	2401 4TH AVENUE, SUITE 1050, SEATTLE WA 98121
Shawnte Mitchell	officer: SVP, GC and Corporate Affairs	5959 HORTON STREET, SUITE 500, EMERYVILLE CA 94608
Michael Adelman	officer: SVP, Commercial Operations	2401 4TH AVENUE, SUITE 1050, SEATTLE WA 98121
Jane A Gross	officer: See Remarks	2401 4TH AVENUE, SUITE 1050, SEATTLE WA 98121